Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation.

HLA - 1 Oct 2023

Betriu Sergi, Rovira Jordi, Arana Carolt, García-Busquets Ainhoa, Matilla-Martinez Marina, Ramirez-Bajo Maria J, Bañon-Maneus Elisenda, Lazo-Rodriguez Marta, Bartoló-Ibars Ariadna, Claas Frans H J, Mulder Arend, Heidt Sebastiaan, Juan Manel, Bayés-Genís Beatriu, Campistol Josep M, Palou Eduard, Diekmann Fritz

Abstract excerpt

The presence of donor-specific antibodies (DSA), mainly against HLA, increases the risk of allograft rejection. Moreover, antibody-mediated rejection (ABMR) remains an important barrier to optimal long-term outcomes after solid organ transplantation. The development of chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy of autoimmune diseases. We aimed to develop a targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to HLA-A2 Antigen

Share to HLA Antigens

Share to Isoantibodies

Share to Receptors, Antigen, T-Cell

Source

Identifiers

PMID: 37503860
DOI: 10.1111/tan.15156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation.PMID 37503860Read ↗

Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipientsSemantic proximity Read ↗

Depletion of alloreactive B cells by chimeric alloantigen receptor T cells with drug resistance to prevent antibody-mediated rejection in solid organ transplantationSemantic proximity Read ↗

Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejectionSemantic proximity Read ↗

Donor-Targeted Anti-HLA-A2 Antibody Shows Nanogram-Level Efficacy in a Novel GVHD Mouse ModelSemantic proximity Read ↗

CAR T-cell therapy - Paving the way for sensitized kidney transplant patientsSemantic proximity Read ↗

Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune toleranceSemantic proximity Read ↗

Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cellsSemantic proximity Read ↗

A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief reviewSemantic proximity Read ↗

Chimeric antigen receptor T cell therapy for autoimmune diseaseSemantic proximity Read ↗

Engineering the Graft–Immune Interface: CAR-T Cell Strategies for Precision Organ TransplantationSemantic proximity Read ↗

A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.Semantic proximity Read ↗

HLA-G engineering reprograms CAR-T cells with an immune privilegeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.